ArticleJournal of diabetes investigation2026
Fasting serum annexin A2 is associated with peripheral insulin sensitivity and may enhance glucose uptake via Src-dependent signaling.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND AND
aimSubcellular annexin A2 (ANXA2) is known to regulate membrane dynamics and GLUT4 trafficking in adipocytes; however, the role of serum ANXA2 in glucose metabolism remains unclear. We aimed to investigate the association between fasting serum ANXA2 and insulin sensitivity in humans and to examine the role of extracellular ANXA2 in glucose uptake in cultured skeletal myocytes.
methodsWe conducted a clinical study in 15 non-diabetic Japanese adults who underwent hyperinsulinemic-euglycemic glucose clamp studies to assess peripheral insulin sensitivity. Fasting serum ANXA2 levels were measured and correlated with metabolic parameters. Cultured C2C12 myotubes were treated with recombinant human ANXA2 and the effects of ANXA2 on glucose uptake and insulin signaling mediators were evaluated.
resultsFasting serum ANXA2 showed a significant positive correlation with mean glucose infusion rate (mean GIR; r = 0.76, P = 0.00095). In C2C12 myotubes, both ANXA2 and insulin significantly increased glucose uptake compared with controls. ANXA2 enhanced IRS-1 and Akt phosphorylation independently of insulin, and this effect was suppressed by the Src-kinase inhibitor PP2.
conclusionsIn conclusion, these results indicated that fasting serum ANXA2 is associated with peripheral insulin sensitivity in humans, and that exogenous ANXA2 may enhance glucose uptake in association with IRS-1/Akt signaling and Src-dependent pathways. Together, these findings support further evaluation of serum ANXA2 as a potential indicator reflecting peripheral insulin sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.